Navigation Links
Rapid-Acting Antidepressants Reviewed by NeuroPerspective

CARDIFF, Calif., Dec. 11, 2012 /PRNewswire/ -- NI Research has released the December issue of NeuroPerspective, which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the programs developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine.

This 29-page issue includes:
1) An overview of the biology of depression and the implications of accelerated treatment effect for our understanding of depression and pathways for intervention.

2) A review of the many therapeutic strategies that are currently under development, with a special focus upon glutamatergic approaches, those which access the NMDA receptor and associated modulator components. These constitute the pathways for RAADs, where symptom relief may occur in hours, rather than weeks.

Among the programs reviewed, the leaders in the race for a RAAD include:

Naurex, whose Phase IIa data for IV GLYX-13 was just released. In spite of the fact that this was a 116pt dose-ranging study in TRD patients, limited by the small cohort sizes for each of the active treatment groups, GLYX-13 exceeded expectations. Most importantly, none of the doses produced psychotomimetic effects in any patients. The pilot study now requires confirmation from the multiple-dose PhIIb trial underway.

Various Ketamine and Ketamine-combination drugs: These programs are hoping to skirt the risk of psychotomimesis via a variety of tactics. Programs in this vein are underway at JNJ/Addex, Lilly, AstraZeneca, Washington University, Yale, and Mt. Sinai.

AstraZeneca's IV AZD6765 has been tested more extensively than most of its competitors, but it is relatively slow to achieve therapeutic effect, and psychotomimetic concerns are not completely alleviated.

Naurex has an orally bioavailable version of GLYX-13, NRX-1074, approaching IND-readiness. If it emulates GLYX-13's impact and safety, NRX-1074 would widen the scope of Naurex's market across the full range of depression. In terms of other oral glutamatergic options, companies involved in this area include: NeurOp/Bristol Myers Squibb, Lilly, Roche, BrainCells, and Vanderbilt University.

Alkermes' ALKS5461 program has the burden of its opioid legacy, which would almost certainly result in Schedule II placement, and what may be some initial euphoric/intoxicant effects.

Other depression programs of note include:

Vortioxetine, the triple amine reuptake inhibitor from Lundbeck/Takeda, in NDA-preparation, and Euthymics Bioscience with its triple amine drug, amitifadine. Forest/Pierre Fabre's levomilnacipran is having its NDA prepared. Methylation Sciences is developing a reformulation of SAMe that they believe has much better bioavailability. This could be of interest to patients and prescribers who would perceive it as less "drug," more "nutriceutical."

3) Other neurotherapeutic stories of note in the December issue include:

The successful Phase III results for Acadia Pharmaceuticals' pimavanserin.

An illuminating graphic comparison of the six-month efficacy results for EnVivo's EVP-6124 and Lilly's solanezumab.

About NI Research
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analysis of therapeutics-in-development.

A one-year subscription to NeuroPerspective is $2,300. The December issue of NeuroPerspective is available for $300 as a single-issue purchase.

NI Research also publishes NeuroLicensing, the Private CNS Company Review, and NeuroSynopsis, a monthly four-page summary of highlights from NeuroPerspective. NIR also provides consulting services to the pharma industry regarding licensing and strategic planning.

Further information and online purchasing with immediate delivery are available at

SOURCE NI Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Peer Reviewed Clinical Study Shows New Blood Test More Accurately Predicts Risk Of A Heart Attack
2. Alzheimers Therapeutics Reviewed by NeuroPerspective
3. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
4. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation ... on being named to Deloitte's 2015 Technology Fast 500 list of the fastest ... AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):